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Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age group and is associated with a
higher cardiovascular risk. Obesity, mainly visceral adiposity, is prevalent in patients with PCOS. Obesity is associated with low-
grade inﬂammation and raised inﬂammatory cytokines, both of which are also described in patients with PCOS. In this paper, the
potential relationships between fat distribution, adipocyte dysfunction and, altered inﬂammatory markers in patients with PCOS
have been discussed.
1.ObesityinPolycysticOvarySyndrome
(PCOS)
PCOS is one of the most common endocrine disorders in
women of reproductive age with a prevalence of 5%–7% [1–
3]. PCOS is associated with a broad range of adverse seque-
lae, including hypertension, dyslipidemia, insulin resistance,
hyperandrogenaemia, gestational and type 2 diabetes, which
ultimately increase the risk of cardiovascular morbidity
[4–12]. Obesity is present in varying degrees in women
with PCOS and is associated with hyperandrogenaemia and
insulin resistance [13].
2.InﬂammatoryMediatorsinObesity
Obesity is associated with a state of chronic systemic
inﬂammation manifested by increased serum levels of
inﬂammatory cytokines as well as alterations in peripheral
blood lymphocyte frequencies and function [14–16]. These
changes are present not only at the tissue level but also in
adipose, liver, and other tissue beds [17, 18]. This inﬂam-
matory process could be the underlying cause of obesity-
relatedcomorbidities,includingatherosclerosis,diabetesand
steatohepatosis [19–23].
Obesity-related inﬂammation is often considered a dis-
order of innate immunity. However, there is a signiﬁcant
crosstalk between innate and adaptive immune systems, and
indeed disorders of both innate and adaptive immunity have
beenimplicatedinobesity-relatedinﬂammation[17,24,25].
Inﬂammation is not only an acute response to trauma
or infection, it is also a response to the ongoing processes
of cell turnover associated with aging [26]. In this regard,
the inﬂammatory response regulates fundamental processes
intrinsic to cellular homeostasis, including proliferation,
necrosis,andapoptosis.Inkeepingwiththetaskofregulating
tissue turnover, inﬂammatory responses are triggered not
only by exogenous stimuli, but also by endogenous stimuli,
such as the by-products of cell necrosis and apoptosis. For
example,freefattyacids,systemiclevelsofwhichareelevated
in obesity, are primary ligands for Toll-like receptors, central
regulators of the innate immune response [27, 28]. Free fatty
acids and Toll-like receptors therefore act as a direct link
between the systems that regulate obesity and inﬂammation.
At the molecular level, the intracellular signalling path-
ways that govern inﬂammation and glucose homeostasis
demonstrate signiﬁcant crosstalk and share multiple sig-
nalling mediators. At the cellular level, adipocytes and
macrophages are closely related and likely evolved from a2 Mediators of Inﬂammation
common primordial precursor cell [29], further evidence
of the parallel evolution of inﬂammation and metabolic
systems.
3. Inﬂammationand InsulinResistance in
PolycysticOvarySyndrome
Approximately 60%–70% of PCOS patients are obese [30],
with a central body fat distribution pattern described as vis-
ceral obesity that is well known to be highly associated with
insulin resistance. However, PCOS patients have evidence of
insulin resistance independent of obesity [31–33]. Insulin
sensitivity is decreased by 35%–40% in women with PCOS,
independent of obesity, a decrease similar in magnitude to
that seen in T2DM mellitus [34]; however, any degree of
obesity further impairs insulin action. About 50%–70% of
all women with PCOS have some degree of insulin resistance
[35]. It is now evident that PCOS has major metabolic
consequences related to insulin resistance. Insulin resistance
is associated with an increased risk for several disorders,
including type 2 diabetes, hypertension, dyslipidemia (low
high-density lipoprotein cholesterol and high triglycerides),
elevated plasminogen activator inhibitor type 1 (PAI-1),
elevated endothelin-1, endothelial dysfunction, and heart
disease.
Data have demonstrated a correlative as well as causative
relationship between insulin resistance and inﬂammation
[36]. Subclinical inﬂammation and insulin resistance are
important predictors of cardiovascular disease [37]. Further-
more, in light of the role of insulin resistance in PCOS and of
the increased cardiovascular risk of aﬀected women, a rela-
tionship between inﬂammation and hormonal-metabolic
features of women with PCOS has been demonstrated [38].
According to Rotterdam consensus criteria commonly
used in clinical practice, two of the following three must be
fulﬁlled for the diagnosis of PCOS: polycystic ovaries (12 or
more follicles in each ovary, each follicle measuring 2–9mm
in diameter and/or ovarian volume >10mL, one polycystic
ovary is suﬃcient for the diagnosis), oligo-/anovulation;
clinically diagnosed as oligo-/amenorrhea (menstrual cycles
longer than 35 days or less than 10 menstruations per year)
and hyperandrogenism (clinical or biochemical) [39]. In
this consensus insulin resistance, metabolic syndrome, and
obesity are not included in the diagnostic criteria to identify
PCOS. However it is possible that some phenotypes of PCOS
(i.e., those characterised by polycystic ovaries and oligo-
menorrhea as per Rotterdam consensus criteria) may simply
reﬂect abnormal androgen and/or LH production without
having metabolic implications.
It has been reported that women with PCOS have
signiﬁcantly increased hs-C-reactive protein (hs-CRP) con-
centrations [40], suggesting CRP a marker of low-grade
inﬂammation, as a predictor of coronary heart disease and
cardiovascular events in PCOS that is also independently
related to insulin resistance. The leukocyte count was found
to be signiﬁcantly higher in women with PCOS compared
with healthy women, although no case of leukocytosis was
found in either group [38]. Regarding the leukocyte diﬀeren-
tial,signiﬁcantincreasesinlymphocytesandmonocyteswere
observed in women with PCOS compared with controls,
which might have been expected considering that they
play a key role in the pathophysiological mechanism of
atherosclerosis [38]. Inﬂammation has been recognised to
play a central role in both initiation and progression of
the atherosclerotic process; therefore, an elevated leukocyte
count should be directly associated with increased incidence
of coronary heart disease, ischemic stroke, and mortality
from cardiovascular disease [41].
In patients with PCOS circulating levels of tumour
necrosis factor α (TNF α), interleukin (IL)-6, hs-CRP, as
well as white blood count (WBC) and neutrophil count
h a v eb e e nf o u n dt ob ee l e v a t e dc o m p a r e dw i t ha g e -a n d
/body mass index- (BMI-) matched controls [40, 42, 43].
In contrast, it has been shown that obesity, and not PCOS
status per se, was a major determinants of the circulating
inﬂammatory markers TNF α, soluble type 2 TNF receptor,
IL-6, and hs-CRP [44, 45]. Increase in both low-grade
chronic inﬂammation and insulin resistance in women with
PCOS is associated with increased central fat excess rather
thanPCOSstatus[46].Furthermore,TNFαisoverexpressed
in adipose tissue [47] and induces insulin resistance through
acute and chronic eﬀects on insulin-sensitive tissues. The
source of excess circulating TNF α in PCOS is likely to be
adipose tissue in the obese but remains unknown in lean
womenwiththedisorder.However,increasedvisceralobesity
couldbeasourceofexcessTNF αin leanwomenwithPCOS.
Another proinﬂammatory cytokine is IL-18, which was
reported to be increased in PCOS [48]. IL-18 induces the
production of TNF α which promotes the synthesis of
IL-6, which is also considered a strong risk marker for
cardiovascular disease [49]. Collectively, the above ﬁndings
indicate that low-grade chronic inﬂammation could be a
novel mechanism contributing to increased risk of coronary
heart disease in PCOS.
Abdominal obesity is largely prevalent in obese women
with PCOS [50]. Because of this, it is not surprising
that the same alterations of abdominal obesity have been
found in obese women with PCOS. In fact, compared
with normal weight controls, obese women with PCOS
present lower levels of adiponectin [51], increased levels
of PAI-1 [52], increased activity of the angiotensin-renin
system [53, 54], and increased cytokines and inﬂammatory
markers [41]. However, obese patients with PCOS have
more severe insulin resistance and higher androgen levels
in comparison with non-PCOS women with abdominal
obesity. Since both of these factors may aﬀect adipocyte
function, it is important to understand whether there are
diﬀerences in production of adipose factors between obese
women with PCOS and non-PCOS women with abdominal
obesity. There were no diﬀerences in levels of leptin, resistin,
and adiponectin between obese women with PCOS and
obese controls [55]. There were also no diﬀerences in levels
of TNF α, IL-6, and markers of inﬂammation between
obese women with PCOS and obese controls [41, 44]. A
signiﬁcant increase in PAI-1 levels between obese women
with PCOS and obese controls has been reported [56].
However, comparing normal-weight patients with PCOS
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PCOS have higher serum levels of PAI-1, TNF α and lower
adiponectin than normoweight controls [41, 53, 55]. All
these data suggest that normoweight women with PCOS
have an increased production of adipokines that is similar to
that found in abdominal obesity. Since these patients present
a mild hyperinsulinemia and insulin resistance [57], it is
possible that it is suﬃcient to alter the adipocyte function.
Consistent with this hypothesis, serum PAI-1 correlates with
serum insulin in normoweight women with PCOS [58, 59].
However, in the same group of patients, no correlation was
found between serum adiponectin [55] or serum TNF α [41]
and serum insulin levels or indices of insulin resistance. Even
in overweight patients with PCOS no correlation between
serum adiponectin and serum insulin or indices of insulin
resistance was found [55].
Abundant leptin receptors have been detected in ovarian
granulosa and theca cells [60]; furthermore, leptin treatment
of these cells in vitro caused signiﬁcant reduction in their
steroid output [61]. It is possible that leptin has a dual
eﬀect on reproduction and that the major site of action
diﬀers according to the circulating levels [62]. Initial reports
suggested that a substantial proportion of women with
PCOS have leptin levels that are higher than expected for
their BMI [63]. However subsequent studies have provided
evidence that circulating leptin levels are fully accounted for
by the degree of adiposity and BMI compared to matching
control subjects [64–67]. On the other hand, it has also
been reported that, for any given body weight, circulating
leptin concentrations are lower in women with PCOS than
those without, suggesting that neuroendocrine recognition
of obesity may be impaired in such women [68].
Hyperinsulinemia alone is likely not suﬃcient to explain
adipocyte dysfunction of normoweight women with PCOS.
Theoretically, normoweight and overweight women with
PCOS may have some degree of visceral obesity that is
insuﬃcient to eﬀect an increase in body weight per se, but
that may be suﬃcient to determine increased production of
some adipokines [55]. On the other hand, visceral obesity
and hyperinsulinemia are generally strictly related, and it is
diﬃcult to separate the two phenomena.
It has been shown that normoweight patients with PCOS
have higher fat accumulation in visceral deposit [69]a n d
lower subcutaneous fat in gluteofemoral area [70]. Although
greater experiences and studies on the correlation between
fat distribution and adipose products in normo-weight and
overweight women with PCOS are needed, the available
data suggest that in these patients, increased abdominal fat
participates in the increased cardiovascular risk. Of course,
insulin resistance is linked to the increase of visceral fat,
and it may contribute to the adipocyte dysfunction of
normoweight women with PCOS.
In conclusion, patients with PCOS present excessive fat
accumulation in visceral deposits, and it plays an important
role in their increased cardiovascular disease. This altered
fat distribution is present not only in the obese, but also in
normoweight patients with PCOS. Altered fat distribution
and adipocyte dysfunction along with chronic lowgrade
inﬂammation could be a novel mechanism contributing to
increase in cardiovascular risk in PCOS.
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